Gilead to acquire Arcellx for $7.8 billion
23/02/2026 11:04
Feb 23 (Reuters) - Gilead Sciences GILD.O said on Monday it will buy cancer drug developer Arcellx ACLX.O for an implied equity value of $7.8 billion. (Reporting by Christy Santhosh in Bengaluru; Editing by Leroy Leo) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on Arcellx
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 02:18 PM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Gilead Extends Tender Offer To Acquire Arcellx
U.S. RESEARCH ROUNDUP-Arcellx, Costar Group, Magnite